Switchable in vivo genetic models to identify cancer drug targets

Obiettivo

The use of classical, germ-line genetics to define gene function in vertebrates is severely limited by embryonic lethality, developmental compensation and adaptive functional degeneracy, all of which obscure the roles played by genes in adult tissues that would normally have developed in the presence of that gene. Consequently, classical germ line knock-out technologies provide only limited information as to the roles of genes in adult tissues and their pathologies. Nowhere is this limitation more profound than in our understanding of cancers, diseases that arise in the main through genetic accidents in established adult tissues and in which defining the ongoing roles of specific genes in maintenance of established tumours is crucial for identifying targets for therapeutic intervention. We will develop a suite of novel technologies for “kinetic genetics” – the rapid and reversible inhibition of specific genes in adult mice, either systemically or in specific tissues. These technologies will not only provide invaluable and novel information concerning gene function in adult tissues but we will use them specifically to define which components of oncogenic networks make the best targets for future cancer therapy.

Campo scientifico

Meccanismo di finanziamento

ERC-AG - ERC Advanced Grant

Istituzione ospitante

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Contributo UE

€ 2 483 235,60

Indirizzo

TRINITY LANE THE OLD SCHOOLS
CB2 1TN Cambridge
Regno Unito

Regione

East of England East Anglia Cambridgeshire CC

Tipo di attività

Higher or Secondary Education Establishments

Ricercatore principale

Gerard Ian Evan (Prof.)

Contatto amministrativo

Renata Schaeffer (Ms.)

Collegamenti

Contatta l’organizzazione Sito web

Costo totale

Nessun dato

Beneficiari (1)